AbbVie Q3 Adjusted EPS $2.95 Beats $2.86 Estimate, Sales $13.93B Beat $13.70B Estimate
Portfolio Pulse from Benzinga Newsdesk
AbbVie reported Q3 earnings of $2.95 per share, beating the analyst consensus estimate of $2.86 by 3.15%. However, this is a 19.4% decrease from the same period last year. The company also reported quarterly sales of $13.93 billion, beating the estimate of $13.70 billion by 1.66%, but this is a 5.97% decrease from last year.
October 27, 2023 | 11:40 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AbbVie's Q3 earnings and sales beat estimates but are lower than the same period last year. This mixed result could lead to uncertain market reactions.
AbbVie's Q3 results exceeded analyst estimates, which is generally a positive signal for the stock. However, the YoY decrease in both earnings and sales might concern investors, potentially offsetting the positive impact of beating estimates.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100